LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
1. LIXTE withdrew SEC registration for its public offering, halting fundraising plans. 2. The registration was not effective, and no securities were sold. 3. LIXTE's LB-100 shows promise in cancer treatment, focusing on activation lethality. 4. No competitors exist for LIXTE's new cancer treatment approach. 5. Clinical trials for LB-100 continue, underpinning LIXTE's innovative strategies.